JP2004525855A5 - - Google Patents

Download PDF

Info

Publication number
JP2004525855A5
JP2004525855A5 JP2001523012A JP2001523012A JP2004525855A5 JP 2004525855 A5 JP2004525855 A5 JP 2004525855A5 JP 2001523012 A JP2001523012 A JP 2001523012A JP 2001523012 A JP2001523012 A JP 2001523012A JP 2004525855 A5 JP2004525855 A5 JP 2004525855A5
Authority
JP
Japan
Prior art keywords
composition
sequence
protein
strain
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001523012A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004525855A (ja
JP5060694B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/025510 external-priority patent/WO2001019380A2/en
Publication of JP2004525855A publication Critical patent/JP2004525855A/ja
Publication of JP2004525855A5 publication Critical patent/JP2004525855A5/ja
Application granted granted Critical
Publication of JP5060694B2 publication Critical patent/JP5060694B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2001523012A 1999-09-17 2000-09-18 腫瘍崩壊性ウイルス Expired - Fee Related JP5060694B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39787399A 1999-09-17 1999-09-17
US09/397,873 1999-09-17
PCT/US2000/025510 WO2001019380A2 (en) 1999-09-17 2000-09-18 Oncolytic virus

Publications (3)

Publication Number Publication Date
JP2004525855A JP2004525855A (ja) 2004-08-26
JP2004525855A5 true JP2004525855A5 (https=) 2007-11-15
JP5060694B2 JP5060694B2 (ja) 2012-10-31

Family

ID=23573018

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001523012A Expired - Fee Related JP5060694B2 (ja) 1999-09-17 2000-09-18 腫瘍崩壊性ウイルス

Country Status (13)

Country Link
EP (2) EP1218019B1 (https=)
JP (1) JP5060694B2 (https=)
CN (1) CN1289098C (https=)
AT (2) ATE319460T1 (https=)
AU (1) AU782402B2 (https=)
CA (1) CA2386920C (https=)
DE (2) DE60026554T2 (https=)
ES (2) ES2260057T3 (https=)
HK (1) HK1044708B (https=)
IL (2) IL148621A0 (https=)
MX (1) MXPA02002772A (https=)
NZ (4) NZ517573A (https=)
WO (1) WO2001019380A2 (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
US7306902B2 (en) 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
US8491884B2 (en) 2000-05-03 2013-07-23 Oncolytics Biotech Inc. Virus clearance of neoplastic cells from mixed cellular compositions
HK1052950B (en) 2000-06-26 2005-06-24 Wellstat Biologics Corporation Purging of cells using viruses
EP1385466B1 (en) 2001-05-11 2011-03-09 Wellstat Biologics Corporation Oncolytic virus therapy
AU2008201293B2 (en) * 2001-07-11 2011-08-18 University Of Miami Recombinant VSV for the treatment of tumor cells
US20030044386A1 (en) * 2001-07-11 2003-03-06 Barber Glen N. Recombinant VSV for the treatment of tumor cells
JP2004099584A (ja) 2002-05-02 2004-04-02 Keio Gijuku Ｈｓｖを用いた抗腫瘍剤
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
US7731974B2 (en) * 2003-03-27 2010-06-08 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and uses thereof
DE602004018284D1 (de) * 2003-03-27 2009-01-22 Ottawa Health Research Inst Mutante vesicular stomatitis viren und deren verwendungen
US8012747B2 (en) 2004-06-01 2011-09-06 San Diego State University Foundation Expression system
CN101065144B (zh) * 2004-08-20 2012-06-13 溶瘤病毒有限公司 治疗血液癌症的方法和组合物
CA2577692C (en) 2004-08-20 2014-05-06 Viralytics Limited Methods and compositions for treatment of hematologic cancers
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
WO2007099401A2 (en) 2005-08-01 2007-09-07 University Technologies International, Inc. Oncolytic attenuated reoviruses for treatment of proliferative disorders
CA2663034C (en) * 2006-09-15 2016-05-03 Ottawa Health Research Institute Oncolytic rhabdovirus
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
JP2011507523A (ja) * 2007-12-21 2011-03-10 ワイス・エルエルシー 遺伝子改変した弱毒化水疱性口内炎ウイルス、組成物およびその使用方法
JP2012500229A (ja) 2008-08-21 2012-01-05 オタワ ホスピタル リサーチ インスティチュート 遺伝子操作された相乗的腫瘍溶解性ウイルス共生
DE102008050860A1 (de) * 2008-10-08 2010-04-15 Dorothee Von Laer LCMV-GP-VSV-Pseudotypvektoren und tumorinfiltrierende Virenproduzentenzellen zur Therapie von Tumoren
US9707285B2 (en) 2009-03-16 2017-07-18 Turnstone Limited Partnership Vaccination methods
CA2836117C (en) * 2009-12-10 2017-08-15 Ottawa Hospital Research Institute Oncolytic rhabdovirus
US9951117B2 (en) 2010-09-02 2018-04-24 Mayo Foundation For Medical Education And Research Vesicular stomatitis viruses
US9428736B2 (en) 2010-09-02 2016-08-30 Mayo Foundation For Medical Education And Research Vesicular stomatitis viruses
CA2872045A1 (en) 2011-06-08 2012-12-13 Children's Hospital Of Eastern Ontario Research Institute Inc. Compositions and methods for glioblastoma treatment
WO2013050048A2 (en) 2011-10-07 2013-04-11 Skau Aps Identification and attenuation of the immunosuppressive domains in fusion proteins of enveloped rna viruses
CA2901501C (en) 2013-02-21 2023-03-07 Children's Hospital Of Eastern Ontario Research Institute Inc. Vaccine composition
DK2983706T3 (en) 2013-04-10 2021-06-14 Univ Aarhus Use of Immune Suppressive Domains as Medicaments
CA2915045A1 (en) 2013-06-14 2014-12-18 Turnstone Limited Partnership Compositions and methods for enhancing virus replication
EP2826856B9 (en) * 2013-07-16 2016-05-04 Sia Latima Genetically stable oncolytic RNA virus, method of manufacturing and use thereof
EP3172562B1 (en) 2014-07-21 2019-03-13 Novellusdx Ltd. Methods and systems for determining oncogenic index of patient specific mutations
CN105233285B (zh) * 2015-09-06 2018-10-12 广州威溶特医药科技有限公司 Epac直接或间接激动剂与溶瘤病毒的联合应用
WO2018213412A1 (en) 2017-05-19 2018-11-22 Georgia State University Research Foundation, Inc. Recombinant oncolytic virus
US10610583B2 (en) 2017-08-31 2020-04-07 Regents Of The University Of Minnesota Methods and compositions for treating glioma and medulloblastoma brain tumors using the zika virus
ES2991089T3 (es) 2017-09-22 2024-12-02 Centre Nat Rech Scient Glicoproteína mutada del virus de la estomatitis vesicular
CN110499297B (zh) * 2019-08-29 2021-07-09 上海市公共卫生临床中心 一种新型溶瘤病毒及其制备方法和应用
CN116724110A (zh) * 2020-08-14 2023-09-08 上海行深生物科技有限公司 重组溶瘤病毒及其构建方法和用途
CA3207359A1 (en) 2021-02-05 2022-08-11 Cecile Chartier-Courtaud Adjuvant therapy for cancer
AU2022227021A1 (en) 2021-02-26 2023-09-21 Kelonia Therapeutics, Inc. Lymphocyte targeted lentiviral vectors
AU2024353243A1 (en) 2023-09-25 2026-04-09 Kelonia Therapeutics, Inc. Antigen binding polypeptides
AU2024353718A1 (en) 2023-09-25 2026-04-09 Kelonia Therapeutics, Inc. Compositions for treating cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1118403B (de) 1960-01-27 1961-11-30 Hoechst Ag Verfahren zur Gewinnung von antitumorwirksamen Sporen
GB1069144A (en) 1963-07-10 1967-05-17 Merck & Co Inc Method for the treatment of malignant tumors
US4806347A (en) 1985-12-11 1989-02-21 Schering Corporation Interferon combinations
CA2132328C (en) 1992-03-24 2000-10-31 Laszlo K. Csatary Vaccine containing live virus for therapy of viral diseases and malignancies
GB9415320D0 (en) 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
US7153510B1 (en) * 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
DE69722608T2 (de) 1996-01-25 2004-04-29 The University Court Of The University Of Glasgow, Glasgow Hsv-mutant-1716 zur behandlung von mesotheliomen
PT1012244E (pt) * 1997-07-11 2007-08-21 Univ Yale ''rabdovírus com revestimentos remanipulados''
IL135507A0 (en) * 1997-10-09 2001-05-20 Pro Virus Inc Treatment of neoplasms with viruses
NZ505312A (en) * 1997-12-22 2003-01-31 Univ Tennesse Res Corp Recombinant Vesicular Stomatitis virus comprising a heterologous F protein (Paramyxovirus strain SV5) and CD4 antireceptor protein
CA2323067A1 (en) * 1998-03-12 1999-09-16 The Trustees Of The University Of Pennsylvania Producer cells for replication selective viruses in the treatment of malignancy
KR100637937B1 (ko) 1998-06-12 2006-10-23 마운트 시나이 스쿨 오브 메디신 오브 뉴욕 유니버시티 변형된 인터페론 길항물질을 보유하고, 백신 및 약제로사용되는 약독화된 네거티브 가닥 바이러스
JP2003530301A (ja) * 1999-04-15 2003-10-14 ウェルスタット バイオロジクス コーポレイション ウイルスを用いた新生物の処置

Similar Documents

Publication Publication Date Title
JP2004525855A5 (https=)
IL148621A (en) Use of a virus for the manufacture of a medicament for reducing the viability of tumor cells and some isolated nucleic acid sequences
Fujioka et al. Interleukin-18 protects mice against acute herpes simplex virus type 1 infection
AU2024203377B2 (en) Altering inflammatory states of immune cells in vivo by modulating cellular activation states
Shinozaki et al. Oncolysis of multifocal hepatocellular carcinoma in the rat liver by hepatic artery infusion of vesicular stomatitis virus
JP2024531486A (ja) 環状ｒｎａを調製するための構築物及び方法
Nakamura et al. Oncolytic measles viruses for cancer therapy
JP2004533449A5 (https=)
ES2296750T3 (es) Forma mutada de la arginina deiminasa.
KR20120049185A (ko) 암 치료용 암 용해성 아데노바이러스
EP1217891A4 (en) THERAPEUTIC PROCEDURES AND COMPOSITIONS USING VIRUSES FROM THE RECOMBINANT FAMILY OF THE PARAMYXOVIRIDAE
NO811973L (no) Ikke-glycosylert interferon.
CN108841796A (zh) 重组单纯疱疹病毒及其制备方法和应用
ATE305801T1 (de) Intratumorale verabreichung nackter il-12 codierender nukleinsäuremoleküle
BRPI0407648A (pt) uso de uma proteìna ligante sìtio-especìfica ativa juntamente com um vetor terapêutico codificando uma proteìna para manufatura de um medicamente
Sakurai et al. Therapeutic effect of intravenous delivery of lipoplexes containing the interferon-β gene and poly I: poly C in a murine lung metastasis model
WO2003092579A3 (en) Compositions and methods for treating cancer with an oncolytic viral agent
EP1545627A4 (en) TARGETED TUMOR THERAPY THROUGH THE USE OF RECOMBINANT ADENOVIRUS VECTORS FOR SELECTIVE REPLICATION IN HYPOXIC TUMOR REGIONS
JP2004532213A5 (https=)
JP2021525517A5 (https=)
Lui et al. Systemic production of IL-12 by naked DNA mediated gene transfer: toxicity and attenuation of transgene expression in vivo
Sato et al. Enhancement of anti-tumor activity of recombinant interleukin-2 (rIL-2) by immunocomplexing with a monoclonal antibody against rIL-2
CN101137391B (zh) 重组高效复合干扰素的用途
JP2005225888A5 (https=)
JP2025141963A (ja) ウイルスを含む抗癌関連非腫瘍細胞剤